Nevirapine toxicity in a cohort of HIV-1-infected pregnant women

American Journal of Obstetrics and Gynecology

Volumn 194, Issue 1, 2006, Pages 199-202

  João, Esau Custódio ^a   Calvet, Guilherme A ^a   Menezes, Jacqueline A ^a   D'Ippolito, Marcos M ^a   Cruz, Maria Letícia S ^a   Salgado, Luisa Andrea T ^a   Matos, Haroldo J ^a  

^a HOSPITAL DOS SERVIDORES DO ESTADO   (Brazil)

Author keywords

HCV; HIV; Nevirapine; Pregnancy; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD4 ANTIGEN; NEVIRAPINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREGNANCY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXICITY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHOLESTASIS; COHORT STUDIES; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME;

EID: 29544446258     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2005.05.015     Document Type: Article

References (15)

1. M. Mirochnick, S. Siminski, T. Fenton, M. Lugo, and J.L. Sullivan Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure Pediatr Infect Dis J 20 2001 803 805
2. D.T. Dieterich, P.A. Robinson, J. Love, and J.O. Stern Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors Clin Infect Dis 38 Suppl 2 2004 80 89
3. S.J. Bersoff-Matcha, W.C. Miller, J.A. Aberg, C. van der Horst, H.J. Hamrick Jr., and W.G. Powderly Sex differences in nevirapine rash Clin Infect Dis 32 2001 124 129
4. J.P. Fagot, M. Mockenhaupt, J.N. Bouwes-Bavinck, L. Naldi, C. Viboud, and J.G. Roujeau Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis AIDS 15 2001 1843 1848
5. E. Martinez, J.L. Blanco, J.A. Arnaiz, J.B. Perez-Cuevas, A. Mocroft, and A. Cruceta Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy AIDS 15 2001 1261 1268
6. D. González de Requena, M. Núñez, I. Jiménez-Nacher, and V. Soriano Liver toxicity caused by nevirapine AIDS 16 2002 290 291
7. L. Martin-Carbonero, M. Núñez, J. Gonzalez-Lahoz, and V. Soriano Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine HIV Clin Trials 4 2003 115 120
8. M.M. de Maat, R. ter Heine, E.C. van Gorp, J.W. Mulder, A.T. Mairuhu, and J.H. Beijnen Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment AIDS 17 2003 2209 2214
9. J. Hitti, L.M. Frenkel, A.M. Stek, S.A. Nachman, D. Baker, and A. Gonzales-Garcia Maternal toxicity with continuous nevirapine in pregnancy - results from PACTG 1022 J Acquir Immune Defic Syndr 36 2004 772 776
10. Bersoff-Matcha SJ, Mundy LM, Henry JV. Adverse events to nevirapine therapy during pregnancy. Eleventh Conference on Retrovirus and Opportunistic Infections [abstract 939]; February 2004; San Francisco, Calif.
11. Gonzalez-Garcia A, Fernandez MI, Cotter A. Nevirapine toxicity in the obstetrical population when used in combination with other antiretrovirals. XV International AIDS Conference 2004 [abstract WePeB5918]; July 2004; Bangkok.
12. J.O. Stern, P.A. Robinson, J. Love, S. Lanes, M.S. Imperiale, and D.L. Mayers A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients J Acquir Immune Defic Syndr 34 Suppl 1 2003 21 33
13. M. Nunez, R. Lana, J.L. Mendoza, L. Martín-Carbonero, and V. Soriano Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy J Acquir Immune Defic Syndr 27 2001 426 431
14. S.G. Edwards, N. Larbalestier, P. Hay, A. de Ruiter, J. Welch, and G.P. Taylor Experience of nevirapine use in a London cohort of HIV-infected pregnant women HIV Med 2 2001 89 91
15. Kramer F, Stek A, Du WB, Kovacs A. Nevirapine tolerability in HIV-infected women in pregnancy. Eleventh Conference on Retrovirus and Opportunistic Infections [abstract 923]; February 2004; San Francisco, Calif.